{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:49:07Z","timestamp":1791535747302,"version":"4.3.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Industry financial ties to the US cancer ecosystem are everywhere. Kim et al.\u2019s systematic review and meta-analysis finds that financial conflicts of interest exceed 50% prevalence across most oncology domains. These relationships are not always benign. A robust body of health services research, including a 2021 systematic review of 36 studies, demonstrates that 83% of analyses identify a positive association between industry payments and prescribing behavior. Even a single industry-sponsored meal costing &amp;lt;$20 has been linked to significantly higher odds of prescribing the promoted drug. As federal National Institute of Health (NIH) funding faces cuts, industry\u2019s role in shaping the research agenda will only expand. Current US policy responses such as the disclosure through the Sunshine Act and dollar thresholds for guideline panelists have had minimal effectiveness in curtailing the money flowing to oncologists. This editorial argues for stronger structural reforms, specifically mandatory cooling-off periods for guideline committee members modeled on existing federal ethics statutes. Disclosure alone is insufficient, and some evidence suggests it may paradoxically license conflicted behavior. Meaningful progress requires moving beyond transparency toward policies that prevent conflicts from influencing clinical decision making.<\/jats:p>","DOI":"10.1093\/jnci\/djag208","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:51:46Z","timestamp":1781869906000},"page":"1802-1804","source":"Crossref","is-referenced-by-count":0,"title":["The floor, not the ceiling: industry ties across the cancer ecosystem"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-8526","authenticated-orcid":false,"given":"Benjamin J","family":"Davies","sequence":"first","affiliation":[{"name":"Chief of the Division of Urologic Oncology, Department of Urology, University of Pittsburgh School of Medicine , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026100903515022100_djag208-B1","article-title":"Prevalence of industry ties in the US cancer ecosystem: a systematic review and meta-analysis","author":"Kim","journal-title":"J Natl Cancer Inst"},{"key":"2026100903515022100_djag208-B2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/M20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing? a systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026100903515022100_djag208-B3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for Medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026100903515022100_djag208-B4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamainternmed.2016.1709","article-title":"Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts","volume":"176","author":"Yeh","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026100903515022100_djag208-B5","doi-asserted-by":"crossref","first-page":"e075512","DOI":"10.1136\/bmj-2023-075512","article-title":"Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study","volume":"383","author":"Mitchell","year":"2023","journal-title":"BMJ"},{"key":"2026100903515022100_djag208-B6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jamainternmed.2018.1999","article-title":"Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing","volume":"178","author":"Hadland","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026100903515022100_djag208-B7","doi-asserted-by":"crossref","first-page":"e186007","DOI":"10.1001\/jamanetworkopen.2018.6007","article-title":"Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses","volume":"2","author":"Hadland","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026100903515022100_djag208-B8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2023.12.011","article-title":"Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States","volume":"181","author":"Murayama","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2026100903515022100_djag208-B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2025.4985","article-title":"Disrupted federal funding for extramural cancer research","volume":"12","author":"Haque","year":"2026","journal-title":"JAMA Oncol"},{"key":"2026100903515022100_djag208-B10","volume-title":"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff on Procedures for Determining Conflict of Interest and Eligibility for Participation in FDA Advisory Committees","author":"US Food and Drug Administration","year":"2012"},{"key":"2026100903515022100_djag208-B11","doi-asserted-by":"crossref","first-page":"pkae120","DOI":"10.1093\/jncics\/pkae120","article-title":"Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy","volume":"8","author":"Saririan","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"2026100903515022100_djag208-B12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2012.154","article-title":"The unintended consequences of conflict of interest disclosure","volume":"307","author":"Loewenstein","year":"2012","journal-title":"JAMA"},{"key":"2026100903515022100_djag208-B13","author":"European Medicines Agency","year":"2024"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag208\/70999001\/djag208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1802\/70999001\/djag208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/10\/1802\/70999001\/djag208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:51:57Z","timestamp":1791532317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/10\/1802\/8788305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag208","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,8]]}}}